Executive Vice President, Representative Director, Shin Nippon Biomedical Laboratories Ltd.
Ken Takanashi has served on Wave’s board of directors for more than ten years and currently serves as Executive Vice President, Representative Director at Shin Nippon Biomedical Laboratories, Ltd. (SNBL), a contract research organization that provides preclinical and clinical services for drug development to pharmaceutical and biotech companies and conducts translational research business. Mr. Takanashi has served in various executive management and director roles at SNBL and its affiliates since 2004. Since 2016, Mr. Takanashi has also served on the board of directors of Satsuma Pharmaceuticals, Inc., a biopharmaceutical company that was previously publicly traded and became a privately held company and wholly owned subsidiary of SNBL on June 8, 2023. Mr. Takanashi also serves as a member of the board of directors of TMS Co., Ltd., a biopharmaceutical company listed on the Tokyo Stock Exchange, since March 2022. Mr. Takanashi has experience working for more than 30 global companies, as well as establishing various biotech companies and contract research organizations. Mr. Takanashi earned an M.B.A. from the University of Warwick and received his bachelor’s degree from the University of Tokyo and is a Chartered Public Accountant.